Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
002603.SZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
+96%
0.57
vs 0.29
Q1.23
+148%
0.72
vs 0.29
Q2.23
-29%
0.24
vs 0.34
Q3.23
-58%
0.09
vs 0.22
Q4.23
N/A
-0.24
vs NA
Q1.24
-75%
0.18
vs 0.72
Q2.24
-44%
0.14
vs 0.24
Q3.24
-84%
0.01
vs 0.09
Q4.24
N/A
-0.77
vs -0.24
Q1.25
+7%
0.2
vs 0.18
Sales Growth
YoY
Current
Estimates
Q1.23
+69%
4.6B vs 2.7B
Q1.23
+45%
3.9B vs 2.7B
Q2.23
+0%
2.9B vs 2.8B
Q3.23
-25%
1.8B vs 2.4B
Q4.23
NA
1.7B vs NA
Q1.24
-37%
2.5B vs 3.9B
Q2.24
-28%
2.1B vs 2.9B
Q3.24
-2%
1.7B vs 1.8B
Q4.24
-91%
147.3M vs 1.7B
Q1.25
-5%
2.4B vs 2.5B
Return on Equity
QoQ
Q2.23
+3%
0.03
vs 0.1
Q3.23
+1%
0.01
vs 0.03
Q4.23
-4%
-0.04
vs 0.01
Q1.24
+3%
0.03
vs -0.04
Q2.24
+2%
0.02
vs 0.03
Q3.24
+0%
0
vs 0.02
Q4.24
-13%
-0.13
vs 0
Q1.25
+3%
0.03
vs -0.13
Institutionnal Ownership
Quote Panel
Key Metrics
Forecast
353%2026-Revenue
317%2026-EPS
359%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
002603.SZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
SHZ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01Â ( 0.07%)
Relative Strenght
Volume Buzz
7%
Earning Acce
No
Dist 52w H.
25%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 002603.SZ compares to sector?
002603.SZ
-35x